Stock Ratings / Health Care / ELUT / financials

EXOZ (36) ESLA (41) ALGS (26) MGX (41) ⌘ Pro Terminal →

Elutia Inc. (Class A) (ELUT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.81 -3.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.80

Elutia Inc. (Class A) (ELUT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $36.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.80 (-0.75%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELUT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY ELUT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 35% of 52W Range • RSI-14 at 53.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.82-3.7% Next Q

Q2 (-2Q)

Grade E$0.79+6.3% Next Q

Q3 (-1Q)

Grade E$0.84-3.6% Next Q

Current

Grade E$0.81-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELUT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELUT currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.85) forces dealer call-delta covering toward $1.46.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ELUT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $12.3M

FY24

Rev $14.5M

FY25

Rev $12.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$12.3M	53.7%	-80%	$53.4M	-$46.7M	-45%
FY 2024	$14.5M	46.4%	-80%	-$53.9M	-$23.3M	-45%
FY 2023	$12.3M	53.7%	-248.3%	-$37.7M	-$21.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELUT)

✓Walkthrough of ELUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.59%▼ DESCENDING CHANNEL

2026-10-30O $0.81H $0.86L $0.80C $0.81VOL 138.3K

RES: $0.89SUP: $0.62SMA50: $0.83SMA200: $0.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELUT Butterfly Map → + Track ELUT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ELUT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELUT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELUT)

Health Care Rank #850 of 1016 ⚔️ EXOZ vs ELUT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELUT vs. EXOZ, ESLA, ALGS, MGX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Elutia Inc. (Class A) (ELUT) ranks #850 by composite RQD confidence (34/100, grade E) and #786 by equity capitalization ($36.0M). Within this direct 5-issuer industry benchmark cohort, ELUT leads on earnings valuation at N/A trailing P/E, while ELUT leads on capital efficiency and profitability with -35.0% ROIC and 53.7% gross margin. ESLA currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ELUT at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELUT ACTIVE Elutia Inc. (Class A)	E	34/100	—	53.7%	-35.0%	-3.13%	$36.0M	Benchmark Subject
EXOZ eXoZymes Inc.	D-	36/100	—	—	-35.0%	-2.72%	$38.2M	/exoz-vs-elut →
ESLA Estrella Immunopharma Inc.	D-	41/100	—	—	-35.0%	-11.32%	$31.7M	/esla-vs-elut →
ALGS Aligos Therapeutics Inc.	E	26/100	—	—	-35.0%	-2.71%	$31.4M	/algs-vs-elut →
MGX Metagenomi Therapeutics Inc.	D-	41/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-elut →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708527

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported GAAP revenue of $12.3M (-15.0% vs. FY2024 revenue of $14.5M ) , GAAP net income of $53.4M, operating cash flow of -$44.8M, and free cash flow of -$46.7M (-100.3% YoY). On the balance sheet, ELUT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$12.3M	$53.4M	-$44.8M	-$46.7M	$62.4M	—
FY2024 (FY)	2024-12-31	$14.5M	-$53.9M	-$22.7M	-$23.3M	$36.1M	$22.6M
FY2023 (FY)	2023-12-31	$0	-$37.7M	-$21.8M	-$21.8M	—	—

3. ELUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.81 (-3.13% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ELUT ranks #850 in composite RQD confidence.

How does ELUT compare to EXOZ and ESLA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, EXOZ (eXoZymes Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $38.2M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELUT?

Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELUT trading relative to its 50-day, 200-day, and 52-week technical levels?

ELUT last traded at $0.81 (-3.13% on volume of 56,045 shares), positioning the stock -2.41% below its 50-day simple moving average ($0.83) and -16.49% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.50 to $1.39, ELUT sits at the 34.8% percentile with a 14-day RSI of 53.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.91).

ELUT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Elutia Inc. (Class A) (ELUT)?

In FY 2025 (10-K), ELUT converted $12.3M of revenue into a 53.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ELUT RQD Cockpit ELUT 12M Forecast ELUT Earnings & Move ELUT Dividends & DRIP ELUT Insiders & 13F ELUT Whale Options ELUT Profit Sankey ELUT News & Why